Literature DB >> 10857485

Carcinogenesis of primary liver malignancies.

R Dürr1, W H Caselmann.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common tumors in humans today, and its incidence has been rising over recent decades in Western countries. The main risk factors for the development of HCC are viral infections (hepatitis B and C), alcohol use, and the intake of mycotoxins in some areas of the world. In addition to these risk factors, genetic disorders such as hemochromatosis or alpha1-antitrypsin deficiency play a role. Regardless of the etiology, HCC generally develops on the basis of liver cirrhosis. Various pathomechanisms are effective during the neoplastic transformation of the hepatocyte. In chemical experimental models, hepatocarcinogenesis occurs in three stages: initiation, progression, and promotion. Molecular mechanisms of HCC development include the alteration in growth factor and tumor suppressor gene expression, dysregulation of apoptosis, and occurrence of reactive oxygen species generated during inflammation.

Entities:  

Mesh:

Year:  2000        PMID: 10857485     DOI: 10.1007/s004230050259

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  12 in total

1.  Construction and expression of recombined human AFP eukaryotic expression vector.

Authors:  Li-Wang Zhang; Jun Ren; Liang Zhang; Hong-Mei Zhang; Bin Jin; Bo-Rong Pan; Xiao-Ming Si; Yan-Jun Zhang; Zhong-Hua Wang; Yang-Lin Pan; Stephen M Festein
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

2.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Molecular genetics of hepatocellular neoplasia.

Authors:  Shilpa Jain; Shashideep Singhal; Peng Lee; Ruliang Xu
Journal:  Am J Transl Res       Date:  2010-01-23       Impact factor: 4.060

4.  Regulation of Aspartyl-(Asparaginyl)-β-Hydroxylase Protein Expression and Function by Phosphorylation in Hepatocellular Carcinoma Cells.

Authors:  Diana L Borgas; Jin-Song Gao; Ming Tong; Nitin Roper; Suzanne M de la Monte
Journal:  J Nat Sci       Date:  2015-04-01

5.  Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection.

Authors:  Jamal Sarvari; Zahra Mojtahedi; Yasuhiro Kuramitsu; Seyed-Ali Malek-Hosseini; Mahmoud Shamsi Shahrabadi; Abbas Ghaderi; Kazuyuki Nakamura
Journal:  Oncol Lett       Date:  2011-05-31       Impact factor: 2.967

6.  Potential Role of Phosphorylation as a Regulator of Aspartyl-(asparaginyl)-β-hydroxylase: Relevance to Infiltrative Spread of Human Hepatocellular Carcinoma.

Authors:  Diana L Borgas; Jin-Song Gao; Ming Tong; Suzanne M de la Monte
Journal:  Liver Cancer       Date:  2015-06-05       Impact factor: 11.740

7.  Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo.

Authors:  W Jiao; K Miyazaki; Y Kitajima
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

8.  Phosphorylation Modulates Aspartyl-(Asparaginyl)-β Hydroxylase Protein Expression, Catalytic Activity and Migration in Human Immature Neuronal Cerebellar Cells.

Authors:  Ming Tong; Jin-Song Gao; Diana Borgas; Suzanne M de la Monte
Journal:  Cell Biol (Henderson, NV)       Date:  2017-06-19

9.  Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro.

Authors:  Ruta Aldonyte; Lennart Jansson; Sabina Janciauskiene
Journal:  BMC Cell Biol       Date:  2004-03-29       Impact factor: 4.241

10.  The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma.

Authors:  Y Fujita; A Shibata; I Ogimoto; Y Kurozawa; T Nose; T Yoshimura; H Suzuki; N Iwai; R Sakata; S Ichikawa; A Tamakoshi
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.